<DOC>
	<DOC>NCT00335166</DOC>
	<brief_summary>This is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 as monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.</brief_summary>
	<brief_title>SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Diagnosis of idiopathic Parkinson's Disease, Modified Hoehn &amp; Yahr up to stage III, UPDRS motor score (part III) must have a total of at least 10 at baseline. Diagnosis is unclear or a suspicion of other parkinsonian syndromes, Patients who have undergone surgery for the treatment of PD, Current presence of dyskinesias, Motor fluctuations or loss of postural reflexes, A history of nonresponse to an adequate course of ldopa or a dopamine agonist, Patients for whom previously treatment with dopamine agonists needed to terminate because of induction of psychosis (i.e. hallucinations) and /or sleep attacks.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Parkinson Disease</keyword>
</DOC>